RNXT
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
RenovoRx, Inc. (RNXT) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.
Quantitative Factor Evaluation • Updated
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | B- (2.9) | A+ (4.5) | B- (3.1) | B (3.4) | C+ (2.6) | B (3.3) |
| 2026-11-07 | B- (2.9) | A+ (4.5) | B- (3.1) | B+ (3.8) | C+ (2.7) | B (3.4) |
| 2026-10-31 | C+ (2.8) | A+ (4.5) | B (3.2) | A (4.3) | C+ (2.7) | B+ (3.5) |
| 2026-10-24 | C+ (2.8) | A (4.5) | B (3.2) | A (4.4) | C+ (2.6) | B+ (3.5) |
Showing the last month only. Subscribe for the full factor score history.
For more — Subscribe